Menu
Search
|

Menu

Close
X

Valeant Pharmaceuticals International Inc VRX.TO (Toronto Stock Exchange)

23.70 CAD
+0.38 (+1.63%)
As of Feb 16
chart
Previous Close 23.32
Open 23.33
Volume 1,343,525
3m Avg Volume 2,154,097
Today’s High 23.94
Today’s Low 23.33
52 Week High 30.56
52 Week Low 11.20
Shares Outstanding (mil) 347.33
Market Capitalization (mil) 5,024.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY17
4,342
FY16
9,674
FY15
12,596
EPS (USD)
FY17
1.683
FY16
-6.917
FY15
-0.484
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
0.54
5.77
Price to Book (MRQ)
vs sector
1.28
5.41
Price to Cash Flow (TTM)
vs sector
3.62
23.42
Total Debt to Equity (MRQ)
vs sector
728.49
16.52
LT Debt to Equity (MRQ)
vs sector
703.33
12.22
Return on Investment (TTM)
vs sector
-2.83
14.43
Return on Equity (TTM)
vs sector
-24.78
16.13

EXECUTIVE LEADERSHIP

Joseph Papa
Chairman of the Board, Chief Executive Officer, Since 2016
Salary: $980,769.00
Bonus: $9,125,000.00
Paul Herendeen
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $346,154.00
Bonus: $10,400,000.00
Christina Ackermann
Executive Vice President, General Counsel, Since 2016
Salary: $230,769.00
Bonus: $1,800,000.00
Thomas Appio
Executive Vice President, Company Group Chairman, International, Since 2016
Salary: --
Bonus: --
William Humphries
Executive Vice President, Company Group Chairman, Dermatology, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2150 Saint-Elzear Blvd W
LAVAL   QC   H7L 4A8

Phone: +1514.7446792

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

SPONSORED STORIES